Headlines about Array BioPharma (NASDAQ:ARRY) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Array BioPharma earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.4398701367262 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have impacted Accern’s analysis:
- After Hours Most Active for Oct 16, 2017 : NFLX, PE, F, MAR, ISBC, LB, GE, SYF, LUV, CMCSA, QQQ, ARRY – Nasdaq (nasdaq.com)
- Array BioPharma Inc. (ARRY) is at $12.36 per share and Inovio Pharmaceuticals, Inc. (INO) is listed at $6.24 – Stocks Gallery (stocksgallery.com)
- Array BioPharma Inc. (ARRY) Good-Looking Institutional Ownership of 94.80% – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Array BioPharma Inc. (ARRY) is at $12.44 per share and Varex Imaging Corporation (VREX) is listed at $33.02 – Stocks Gallery (stocksgallery.com)
- Dilated Cardiomyopathy Therapeutics Market to Get Bigger at at a CAGR of 4.6% from 2014 to 2020 (mynewsdesk.com)
Several analysts recently commented on the stock. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $18.00 target price (up previously from $14.00) on shares of Array BioPharma in a report on Wednesday, September 20th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $15.00 target price on shares of Array BioPharma in a report on Tuesday, September 26th. J P Morgan Chase & Co reaffirmed a “buy” rating and set a $14.00 target price on shares of Array BioPharma in a report on Monday, September 11th. Stifel Nicolaus reaffirmed a “buy” rating and set a $15.00 target price (up previously from $13.00) on shares of Array BioPharma in a report on Monday, September 11th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $15.00 target price (up previously from $14.00) on shares of Array BioPharma in a report on Monday, September 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $13.36.
Shares of Array BioPharma (ARRY) opened at 12.07 on Tuesday. The company’s market cap is $2.07 billion. Array BioPharma has a 12-month low of $5.36 and a 12-month high of $13.40. The firm has a 50-day moving average of $11.22 and a 200-day moving average of $9.00.
Array BioPharma (NASDAQ:ARRY) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.04. The firm had revenue of $33.80 million during the quarter, compared to the consensus estimate of $28.64 million. Array BioPharma had a negative net margin of 77.44% and a negative return on equity of 1,187.18%. The company’s revenue was down 21.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.17) earnings per share. Analysts predict that Array BioPharma will post ($0.99) EPS for the current year.
In other news, Director Kyle Lefkoff sold 38,865 shares of Array BioPharma stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $12.31, for a total value of $478,428.15. Following the completion of the transaction, the director now owns 51,585 shares in the company, valued at $635,011.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 3.18% of the stock is owned by company insiders.
WARNING: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/10/17/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-array-biopharma-arry-share-price.html.
About Array BioPharma
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).
Receive News & Ratings for Array BioPharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array BioPharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.